*  UPENN Biomedical Graduate Studies | Carolina B. Lopez
Defective Viral Genomes Promote Strong Innate Antiviral Responses During Respiratory Syncytial Virus Infection in Mice and ... such as the influenza virus or the respiratory syncytial virus. These viruses can cause or exacerbate chronic lung diseases, ... Granulocyte colony-stimulating factor protects mice during respiratory virus infections. PLoS One 7(5):e37334, May 2012.. López ... Antiviral instruction of bone marrow leukocytes during respiratory viral infections. Cell host & microbe 7(5): 343-53, May 2010 ...
  http://www.med.upenn.edu/apps/faculty/index.php/g20000320/p8399502
*  administration and dosage - CISMeF
Truvada for pre-exposure prophylaxis to reduce the risk of HIV-1 infection in adults at high risk - recommendations to support ... respiratory syncytial virus infections. antiviral agents. treatment outcome. hospitalization. heart defects, congenital. ... infections of the skin and soft tissue. soft tissue infections. intraabdominal infections. urinary tract infections. sexually ... prosthesis-related infections. prosthesis-related infections. prosthesis-related infections. prosthesis-related infections. ...
  http://www.chu-rouen.fr/page/detail/en/MSH_Q_000008
*  STAT5-Induced Lunatic Fringe during Th2 Development Alters Delta-like 4-Mediated Th2 Cytokine Production in Respiratory...
Respiratory syncytial virus infections: recent prospects for control. Antiviral Res. 71: 379-390. ... Respiratory syncytial virus synergizes with Th2 cytokines to induce optimal levels of TARC/CCL17. J. Immunol. 179: 1648-1658. ... Respiratory syncytial virus (RSV) infects nearly all infants by age 2 and is the leading cause of bronchiolitis in children ... In this study, we investigated the role of Notch activation in a mouse model of respiratory syncytial virus (RSV)-exacerbated ...
  http://www.jimmunol.org/content/192/3/996
*  The Lung Microbiome, Immunity, and the Pathogenesis of Chronic Lung Disease | The Journal of Immunology
... modulate respiratory antiviral immune responses and induce protection against respiratory syncytial virus infection. BMC ... Animal models of respiratory syncytial virus infection have demonstrated that the antiviral response within the lung mucosa can ... Respiratory influenza virus infection induces intestinal immune injury via microbiota-mediated Th17 cell-dependent inflammation ... Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. ...
  http://www.jimmunol.org/content/196/12/4839
*  Novel TLR Inhibitors Prevent Respiratory Syncytial Virus Infection In Vivo
Invention for reducing lung inflammation and infection by increasing the concentration of unsaturated phosphatidylglycerols ( ... Video - POPG, Promising Antiviral. Background. Respiratory Syncytial Virus (RSV) is the most common cause of hospitalization ... Respiratory Syncytial Virus (RSV), influenza A virus, rhinovirus, sepsis-induced ARDS, asthma, reducing the effects of ... for respiratory illness in young children and 90% of children under the age of 2 will be infected by this virus. RSV infection ...
  https://www.nationaljewish.org/research-science/support/tech-transfer/techsum07-07
*  Respiratory syncytial virus infection - ONA
This is particularly so if lower respiratory infection develops.. Available antiviral treatments include ribavirin, IVIG and ... After the age of 2 years, respiratory syncytial virus (RSV) no longer causes a lower respiratory tract infection in the child ... How can respiratory syncytial virus infection be prevented?. The only preventive therapy available to prevent severe RSV ... Are you sure your patient has respiratory syncytial virus infection? What are the typical findings for this disease? * Factors ...
  https://www.oncologynurseadvisor.com/pediatrics/respiratory-syncytial-virus-infection/article/623786/
*  Session: Antimicrobial Agents: PK/PD Studies (IDWeek 2015)
Population PK/PD Modeling of Human Respiratory Syncytial Virus Infection and the Antiviral Effect of AL-8176. Kashyap Patel, ... GS-5806, a Novel Fusion Inhibitor of Respiratory Syncytial Virus Delivers High Respiratory Tract Levels in Preclinical Species ... Vancomycin Exposure Predicts Early Clinical Response in Complicated Skin and Soft Tissue Infections Caused by Methicillin- ... isolates in the Neutropenic Murine Thigh Infection Model. Alexander Lepak, MD ; David Andes, MD, FIDSA ...
  https://idsa.confex.com/idsa/2015/webprogram/Session7281.html
*  Ribavirin Pharmacokinetics
... infections. The exerted antiviral effect depends substantially on dosage and plasma concentration of the drug, thus its ... Ribavirin is a broad spectrum antiviral agent predominantly used in the treatment of hepatitis C and respiratory syncytial ... is a broad spectrum antiviral agent predominantly used in the treatment of hepatitis C and respiratory syncytial virus (RSV) ... infections. The exerted antiviral effect depends substantially on dosage and plasma concentration of the drug, thus its ...
  https://www.news-medical.net/health/Ribavirin-Pharmacokinetics.aspx
*  Antiviral drug - Wikipedia
Nokes JD, Cane PA (December 2008). "New strategies for control of respiratory syncytial virus infection". Curr. Opin. Infect. ... other viruses such as respiratory syncytial virus, parainfluenza virus and adenoviruses can cause them too. Rhinoviruses also ... Nitazoxanide also inhibits the replication of a broad range of other RNA and DNA viruses including respiratory syncytial virus ... One anti-viral strategy is to interfere with the ability of a virus to infiltrate a target cell. The virus must go through a ...
  https://en.wikipedia.org/wiki/Antiviral_drug
*  Protocols and Video Articles Authored by Terianne M. Wong
Expression and Purification of Virus-like Particles for Vaccination' ... Respiratory Syncytial Virus (RSV) Infection in Elderly Mice Results in Altered Antiviral Gene Expression and Enhanced Pathology ... May, 2016 , Pubmed ID: 27215855 Respiratory syncytial virus (RSV) is a significant cause of lower respiratory tract infections ... Delta Inulin-derived Adjuvants That Elicit Th1 Phenotype Following Vaccination Reduces Respiratory Syncytial Virus Lung Titers ...
  https://www.jove.com/author/Terianne++M._Wong
*  Nanobodies® specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion
... we investigated the mechanism by which these nanobodies neutralize RSV and tested their antiviral activity in vivo. We ... Nanobodies® specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion. Bert ... "Nanobodies® Specific for Respiratory Syncytial Virus Fusion Protein Protect Against Infection by Inhibition of Fusion." Journal ... "Nanobodies® Specific for Respiratory Syncytial Virus Fusion Protein Protect Against Infection by Inhibition of Fusion." JOURNAL ...
  https://biblio.ugent.be/publication/1942045
*  Inhibition of T1/St2 during Respiratory Syncytial Virus Infection Prevents T Helper Cell Type 2 (Th2)- but Not Th1-Driven...
Alwan W.H., Kozlowska W.J., Openshaw P.J.M. Distinct types of lung disease caused by functional subsets of antiviral T cells. J ... Simoes E.A. Respiratory syncytial virus and subsequent lower respiratory tract infections in developing countriesa new twist to ... Inhibition of T1/St2 during Respiratory Syncytial Virus Infection Prevents T Helper Cell Type 2 (Th2)- but Not Th1-Driven ... Respiratory syncytial virus (RSV) is a common cold virus that causes bronchiolitis in infants, killing up to one million ...
  http://pubmedcentralcanada.ca/pmcc/articles/PMC2193366/
*  Five significant genes identified after DOE analysis.Mi | Open-i
Respiratory syncytial virus (RSV) infection in elderly mice results in altered antiviral gene expression and enhanced pathology ... Respiratory Syncytial Virus Infections/genetics*/immunology/pathology/physiopathology*. *Respiratory Syncytial Viruses/ ... Respiratory Syncytial Virus Infections/genetics*/immunology/pathology/physiopathology*. *Respiratory Syncytial Viruses/ ... Respiratory syncytial virus (RSV) infection in elderly mice results in altered antiviral gene expression and enhanced pathology ...
  https://openi.nlm.nih.gov/detailedresult.php?img=PMC3928298_pone.0088764.g004&req=4
*  Research programme: antivirals - Vivaldi Biosciences - AdisInsight
Vivaldi Biosciences was developing small molecule antiviral drugs for the treatment of respiratory diseases caused by negative- ... Discontinued Parainfluenza virus infections; Respiratory syncytial virus infections Most Recent Events * 23 Jan 2014 ... 23 Jan 2014 Discontinued for Respiratory syncytial virus infections in USA (unspecified route) ... Discontinued for Parainfluenza virus infections in USA (unspecified route) * ...
  http://adisinsight.springer.com/drugs/800031524?error=cookies_not_supported&code=ba723dcb-1a0a-43f4-80b1-f998d48d3bfd
*  Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infecte... ( MILFORD Mass. May 23 2013 /-...
Unlike other classes of drugs for HCV infection that act directly on ...,Spring,Bank,Pharmaceuticals,Initiates,a,Phase,I, ... Company also has preclinical programs for the development of immune-modulating therapies against Respiratory Syncytial Virus ( ... RSV) infections, a Broad-Spectrum Antiviral, and a SMNH based therapy to treat Chronic Obstructive Pulmonary Disease (COPD). ... "Unlike other classes of drugs for HCV infection that act directly on the virus, SB 9200 targets host cytosolic sensor proteins ...
  http://www.bio-medicine.org/medicine-technology-1/Spring-Bank-Pharmaceuticals-Initiates-a-Phase-I-Clinical-Trial-for-SB-9200-in-HCV-infected-Patients-33246-1/
*  Gilead's RSV drug clears mid-stage trial - PMLiVE
Gilead Sciences has moved a stage closer to bringing the first antiviral drug for respiratory syncytial virus (RSV) infection ... antiviral therapy GS-508 would be an important addition to the armamentarium of drugs for severe respiratory infections if ... showing that it was able to limit RSV infection in adult patients who were given an intranasal dose of the virus. ... Healthy patients who contract RSV generally recover with no long-term ill effects, but the infection can be hazardous in the ...
  http://www.pmlive.com/pharma_news/gileads_rsv_drug_clears_mid-stage_trial_571500
*  Novel Therapeutics against Respiratory Syncytial Virus Infection - Richard Plemper
Respiratory syncytial virus (RSV), a member of the paramyxovirus family, is the leading cause of infant hospitalization from ... Influenza Virus and Respiratory Syncytial Virus Luciferase Reporter Strains Engineered for Co-Infections Identify Antiviral ... Novel Therapeutics against Respiratory Syncytial Virus Infection Plemper, Richard K. Georgia State University, Atlanta, GA, ... Novel Therapeutics against Respiratory Syncytial Virus Infection. Plemper, Richard K. / Georgia State University. $497,303. ...
  http://grantome.com/grant/NIH/R01-HD079327-01
*  Antivirals (non-HIV drugs) - Cancer Therapy Advisor
Cancer Therapy Advisor provides hospital infection control specialists with the latest information to control infectious ... "ontrol of an outbreak of respiratory syncytial virus infection in immunocompromised adults". J Hosp Infect. vol. 44. 2000. pp. ... "Aerosolized ribavirin treatment of respiratory syncytial virus infection in infants hospitalized during an epidemic". Pediatr ... Policy Statement - Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections". ...
  http://www.cancertherapyadvisor.com/hospital-infection-control/antivirals-non-hiv-drugs/article/598661/
*  Aviragen Therapeutics - Current Report
... a fusion protein inhibitor in development for the treatment of respiratory syncytial virus infections; and BTA074, an antiviral ... Development of the non-nucleoside inhibitor program for the treatment of respiratory syncytial virus (RSV) infections continues ... a company focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that ... Vapendavir : The Company is evaluating a potential clinical development path for the drug based on the consistent antiviral ...
  http://investors.biotapharma.com/secfiling.cfm?filingID=1437749-17-6054&CIK=72444
*  Keystone Symposia | Scientific Conferences on Biomedical and Life Science Topics
Respiratory Syncytial Virus Manipulation of the Anti-Viral Cytokine Response Facilitates Infection and Contributes to ... Early Events in the T cell Response to Respiratory Virus Infection. Jack R. Bennink, NIAID, National Institutes of Health, USA ... Short Talk: Distribution of Virus-Specific Memory B Cells Following Influenza Infection of the Respiratory Tract. ... Nancy A. Jewell, Lovelace Respiratory Research Institute, USA Type I Interferon Induction by Respiratory Viruses in vivo. ...
  http://www.keystonesymposia.org/index.cfm?e=web.Meeting.Program&meetingid=801
*  Kleenex Anti-Viral Facial Tissues, 1,224 sheets - BJ's Wholesale Club
Respiratory Syncytial Virus (RSV - the leading cause of lower respiratory infection in children) ... Be proactive during cold and flu season by keeping Kleenex Anti-Viral facial tissues on hand for a friend, stranger or yourself ... With three soft layers, including a moisture-activated middle layer that kills 99.9% of cold and flu viruses, these 3-ply ...
  http://www.bjs.com/kleenex-anti-viral-facial-tissues-1224-sheets.product.3000000000001049602
*  Aviragen Therapeutics - Quarterly Report
... an oral fusion protein inhibitor in development for the treatment of respiratory syncytial virus infections; and BTA074, a ... We are focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic ... an oral fusion protein inhibitor in development for the treatment of respiratory syncytial virus ('RSV') infections; and BTA074 ... rate of progression of RV in upper respiratory tract infection to lower respiratory tract infection, duration of RV shedding in ...
  http://investors.biotapharma.com/secfiling.cfm?filingID=1437749-17-1767&CIK=72444
*  Aviragen Therapeutics Announces Top-Line Results from Phase 2a RSV Challenge Study of BTA585 (NASDAQ:AVIR)
Nasdaq:AVIR), a company focused on the discovery and development of the next generation of direct-acting antivirals to treat ... infections that have limited therapeutic options, today announced top-line data from its double-blind, placebo-controlled Phase ... an oral fusion protein inhibitor in development for the treatment of respiratory syncytial virus infections; and BTA074, a ... is focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have ...
  http://investors.biotapharma.com/releasedetail.cfm?releaseid=1010067
*  Human cathelicidin, LL-37, inhibits respiratory syncytial virus infection in polarized airway epithelial cells | BMC Research...
Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model. Eur Respir J. ... LL-37CathelicidinRespiratory syncytial virusAir-liquid interfaceCalu-3. Findings. Respiratory syncytial virus (RSV) is a major ... Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without ... Evaluation of the Calu-3 cell line as a model of in vitro respiratory syncytial virus infection. J Virol Methods. 2011;174(1-2 ...
  https://0-bmcresnotes-biomedcentral-com.brum.beds.ac.uk/articles/10.1186/s13104-015-1836-y
*  Building a better neonatal mouse model to understand infant respiratory syncytial virus disease. | Sigma-Aldrich
Respiratory syncytial virus (RSV) is the number one cause of lower respiratory tract infection in infants; and severe RSV ... infection in infants is associated with asthma development. Today, there are still no vaccines or specific antiviral therapies ... Respiratory research 2015-8-2 Building a better neonatal mouse model to understand infant respiratory syncytial virus disease. ... As with primary infection, reinfection with rA2-19F induced similar but exaggerated Th2 and reduced Th1 and effector CD8(+) T ...
  https://www.sigmaaldrich.com/catalog/papers/26231396